Literature DB >> 3721935

The incidence of late endocrine dysfunction following irradiation for childhood medulloblastoma.

O K Abayomi, A Sadeghi-Nejad.   

Abstract

A retrospective analysis of treatment in 20 patients who had received post-operative radiotherapy for medulloblastoma between 1969 and 1977 was completed. The patients were followed for a minimum of 60 months. Eleven patients survived for 5 or more years after treatment. The patients received 3600 cGy to the whole brain. The posterior fossa received 5600 cGY and the spinal axis 3600 cGY. Eight of eleven patients developed growth impairment; 6 of 7 patients had growth hormone deficiency. Since all endocrine gland failures are amenable to therapy, early attention to patients' growth rate and detection of hypothalamic-pituitary failure, would be of benefit to longterm survivors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3721935     DOI: 10.1016/0360-3016(86)90390-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

Review 1.  Endocrine dysfunctions in patients treated for brain tumors: incidence and guidelines for management.

Authors:  A A Brandes; L M Pasetto; F Lumachi; S Monfardini
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

Review 2.  Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Authors:  Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

3.  Growth hormone and segmental growth in survivors of head and neck embryonal rhabdomyosarcoma.

Authors:  J R Katz; P Bareille; G Levitt; R Stanhope
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

4.  Endocrine functions in long-term survivors of low-grade supratentorial glioma treated with radiation therapy.

Authors:  M J Taphoorn; J J Heimans; E A van der Veen; A B Karim
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.